【摘要】 目前,脑胶质瘤的常规治疗尚不能显著改善患者预后,越来越多的研究人员开始关注免疫检查点抑制剂在脑胶质瘤中的治疗作用。本文主要综述了免疫检查点程序性死亡蛋白-1(PD-1)、程序性死亡蛋白配体-1(PD-L1)、细胞毒性T淋巴细胞相关抗原-4(CTLA-4)、T细胞免疫球蛋白和黏蛋白分子-3(TIM-3)、淋巴细胞活化基因-3蛋白(LAG-3)、T细胞免疫球蛋白和ITIM结构域蛋白(TIGIT)、B7-H4和T细胞激活抑制物免疫球蛋白可变区结构域(VISTA)在脑胶质瘤中的表达和作用机制,总结了免疫检查点抑制剂在临床治疗中的研究进展,并对其发展前景进行了展望。更多还原

【Abstract】 Conventional treatment of glioma has not significantly improved the prognosis of patients, so peoplepay more attention to the potential of immuno-checkpoint inhibitors in the treatment of glioma. This article reviewsthe expression and mechanism of some negative immune checkpoints in gliomas, such as programmed death-1(PD-1), programmed death ligand-1(PD-L1), cytotoxic T lymphocyte antigen-4(CTLA-4), T-cell immunoglobulinand mucin-domain containing-3(TIM-3), lymphocyte-activation gene-3(LAG-3), T cellimmunoreceptor with Igand ITIM domains(TIGIT), B7-H4 and V-domain immunoglobulin suppressor of T-cell activation(VISTA), aswell as progress of immune checkpoint inhibitors in clinical research, with a prospect of their future in immuno-therapy.更多还原